China's biotech pipeline now half of global total, STAT reports

Chinese-designed drugs now represent roughly half of the global pipeline, a significant shift in the biotech landscape. STAT's visit to Shanghai highlights the scale and pace of China's biotech innovation, which is increasingly a source of competitive pressure for American firms. The report underscores a structural change in global R&D leadership, though the exact composition and quality of the pipeline remain unspecified.